Ohio Clinical Trials Report — June 2026

For Ohio residents considering participation in clinical research, June 2026 presents both urgent deadlines and exciting new opportunities. A total of 213 clinical trials across the state are slated to close within the next 90 days, meaning time is running out to enroll. This critical window includes 24 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should act quickly to explore trials with impending deadlines. Research focusing on various cancers, neurological conditions, and metabolic disorders are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (6 trials)
• Advanced solid tumor (5 trials)
• Epilepsy (5 trials)
• Stroke (4 trials)
• Endometrial cancer (3 trials)
• Duchenne muscular dystrophy (3 trials)
• Type 2 diabetes (3 trials)
• Major depressive disorder (3 trials)
• Ovarian cancer (3 trials)
• Fallopian tube cancer (2 trials)

A Wave of New Research Across Ohio

This month, Ohio welcomes 60 new clinical trials, a slight increase from the 56 trials that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and crucial vaccine development.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy, safety, and tolerability of aleniglipron.
• Pfizer is leading an important Phase 3 vaccine trial: NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This trial aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants.
• For those with type 2 diabetes, AstraZeneca is also sponsoring NCT07662109, a Phase 3 study investigating "The Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This trial plans for 2,000 participants.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants.
• A significant Phase 4 study, NCT07665268, sponsored by Sequence LifeScience, Inc., is evaluating "Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers." This trial plans to enroll 2,000 participants.
• For bladder cancer detection and surveillance, Convergent Genomics, Inc. is sponsoring NCT07673016, an observational study for "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform." This study aims for 2,500 participants.
• Finally, NCT07623902, sponsored by Jubaan Ltd., is evaluating "Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population," with 1,436 participants.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 60 new trials launched this month, 7 are actively seeking healthy volunteers. Statewide, a total of 290 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and advancing healthcare.

Ohio's Research Landscape: Conditions and Interventions

The 60 new trials opening this month in Ohio cover a diverse range of health conditions, with a strong focus on metabolic health and infectious disease prevention. The most common conditions addressed by these new studies include:

• Type 2 diabetes mellitus (3 trials)
• Obesity (3 trials)
• Heart failure (2 trials)
• Chronic weight management (2 trials)
• Pneumococcal disease (2 trials)
• Chronic pain (2 trials)
• Narcolepsy (2 trials)
• Overweight (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 28 of the new studies. Other types of research include procedures (9), behavioral interventions (8), and devices (8), alongside biological treatments, radiation, and diagnostic tests. Academic institutions and industry sponsors both play vital roles in Ohio's research ecosystem, with Children's Hospital Medical Center, Cincinnati sponsoring 6 new trials, AstraZeneca sponsoring 5, and The Cleveland Clinic sponsoring 4. Overall, 28 new trials are industry-sponsored, while 29 are sponsored by other organizations, including academic centers.

Geographic Accessibility Across Ohio

Ohio's clinical research landscape continues to be robust, with 3,122 clinical trials currently recruiting across 154 cities and 1,717 research sites statewide. This month, the majority of new research initiatives are concentrated in Ohio's major metropolitan areas, ensuring broad access for residents. The cities with the most new trials include:

• Columbus (19 new trials)
• Cincinnati (17 new trials)
• Cleveland (12 new trials)
• Dayton (6 new trials)
• South Euclid (2 new trials)
• Milford (2 new trials)
• West Chester (2 new trials)

While major cities serve as central hubs, new opportunities are also emerging in smaller communities like Wadsworth, Canfield, and Westerville, indicating a continued effort to expand research access throughout the state.

Diverse Participation Welcomed

Clinical trials in Ohio are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 11 include children as participants, and 50 include older adults, ensuring that research benefits diverse age groups. Additionally, 2 new trials are female-only, and 3 are male-only, addressing specific health needs within these populations.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Ohio.